摘要
肿瘤微环境是肿瘤患者化疗疗效的主要障碍之一。肿瘤内的血流异常导致了不均匀的药物分布。电化学疗法(ECT)是一种治疗肿瘤的方法,应用全身或局部给与抗癌药物结合透入适当的振幅和波形的电脉冲。这使抗油脂药物的应用能时常保持在狭窄的治疗指数范围,同时减少病人的发病率和维持合适的抗癌功效。它的使用是针对人类的皮肤肿瘤和减轻皮肤肿瘤转移的治疗,已被修订了标准的操作程序。另一方面,此方法在兽医肿瘤学越来越普及,由于其疗效高、毒性低,从而成为各种临床条件下不同癌症组织分型的一线治疗。本文综述了国家的最先进的兽医肿瘤的临床前模型,并报道了在药物和治疗结合方面取得进展的新的实验方案。
关键词: 佐剂,博莱霉素,顺铂,电穿孔法,新辅助疗法,宠物,治疗指数
Current Cancer Drug Targets
Title:Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
Volume: 16 Issue: 1
Author(s): E. P. Spugnini, T. Azzarito, S. Fais, M. Fanciulli and A. Baldi
Affiliation:
关键词: 佐剂,博莱霉素,顺铂,电穿孔法,新辅助疗法,宠物,治疗指数
摘要: Tumor microenvironment is one of the major obstacles to the efficacy of chemotherapy in cancer patients. The abnormal blood flow within the tumor results in uneven drug distribution. Electrochemotherapy (ECT) is a tumor treatment that adopts the systemic or local delivery of anticancer drugs with the application of permeabilizing electric pulses having appropriate amplitude and waveforms. This allows the use of lipophobic drugs that frequently have a narrow therapeutic index maintaining at the same time a reduced patient morbidity and preserving appropriate anticancer efficacy. Its use in humans is addressed to the treatment of cutaneous neoplasms or the palliation of skin tumor metastases, and a standard operating procedure has been devised. On the other hand, in veterinary oncology this approach is gaining popularity, thus becoming a first line treatment for different cancer histotypes, in a variety of clinical conditions due to its high efficacy and low toxicity. This review summarizes the state of the art in veterinary oncology as a preclinical model and reports the new protocols in terms of drugs and therapy combination that have been developed.
Export Options
About this article
Cite this article as:
E. P. Spugnini, T. Azzarito, S. Fais, M. Fanciulli and A. Baldi , Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols, Current Cancer Drug Targets 2016; 16 (1) . https://dx.doi.org/10.2174/156800961601151218155340
DOI https://dx.doi.org/10.2174/156800961601151218155340 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry Synthesis and Activity of Epothilone D
Current Drug Targets mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry Ruthenium Antimetastatic Agents
Current Topics in Medicinal Chemistry A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Aptamer-Mediated Cancer Gene Therapy
Current Gene Therapy Protein Arrays: Recent Achievements and their Application to Study the Human Proteome
Current Proteomics Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Current Pharmaceutical Design Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules
Current Drug Metabolism Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities
Endocrine, Metabolic & Immune Disorders - Drug Targets The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Statins: A Conceivable Remedial Role for the Regulation of Cancer Progression
Current Cancer Therapy Reviews Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology Novel Drugs Targeting Microtubules: the Role of Epothilones
Current Pharmaceutical Design